Trial Profile
Second phase III trial of forigerimod for systemic lupus erythematosus.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 11 Feb 2020
Price :
$35
*
At a glance
- Drugs Forigerimod (Primary)
- Indications Systemic lupus erythematosus
- Focus Registrational; Therapeutic Use
- 06 Feb 2020 According to ImmuPharma media release, company expects second phase III lupus trial to get underway as soon as possible this year.
- 30 Apr 2015 According to ImmuPharma media release, agreement was signed with Simbec-Orion an international clinical research organisation to under take crucial Phase III clinical trial.
- 13 Aug 2013 New trial record